Kerr L et al., 2022-08-31: Exploratory follow-up of the Itajaí programme claiming a dose-response gradient: regular users had 92% lower COVID-19 mortality than non-users, irregular users 51% lower.
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin.
Kerr L et al., 2022-08-31: Exploratory follow-up of the Itajaí programme claiming a dose-response gradient: regular users had 92% lower COVID-19 mortality than non-users, irregular users 51% lower. Exploratory analysis of a prospective observational study, Itajaí, Brazil; ivermectin 0.2 mg/kg/day for two consecutive days every 15 days for 150 days; 'regular' defined as 180 mg or more in total, 'irregular' as up to 60 mg; comparator non-users. Conflicts, declared in the paper: one author is a paid consultant for Vitamedic, an ivermectin manufacturer, and co-founder of a physicians' group , recorded as neutral disclosure per rule 9. The dose-response claim is the pro-ivermectin answer to the 'too little drug' criticism; the design remains observational with self-selected exposure. This is the paper most often cited for the 'dose matters' argument. Study type: controlled study.
